Nearly half of hemorrhagic stroke survivors experience headaches with no proven treatment.
For nearly half of those who survive a hemorrhagic stroke, the ordeal does not end with the bleeding — it continues in the form of persistent headaches that medicine has yet to learn how to prevent or reliably treat. A meta-analysis of 22 studies, presented at the 2026 American Headache Society meeting, places this prevalence at 46 percent, with women and those who carried a headache history into their stroke at significantly greater risk. The finding is less a discovery than a reckoning: the medical community now has a clear measure of a widespread suffering it has, until now, largely left unaddressed.
- Nearly one in two hemorrhagic stroke survivors develops post-stroke headaches, yet no established treatment protocols exist to help them.
- Patients with a prior history of migraines or tension headaches face nearly five times the risk — a vulnerability that arrives with them into the stroke ward.
- The headache rates held steady across geographies and healthcare settings, ruling out research bias and confirming this is a universal, not regional, burden.
- Clinicians are left navigating a common complication with almost no clinical trial evidence to guide preventive or therapeutic decisions.
- Researchers are now pressing for standardized diagnostic criteria and rigorous trials — the foundational work that should have begun long ago.
Nearly half of all hemorrhagic stroke survivors will experience headaches in the aftermath of their event — a finding that emerges from a meta-analysis of 22 studies presented at the 2026 American Headache Society annual meeting. Led by Dr. Bradley Ashley Ong of the Cleveland Clinic, the research combed decades of medical literature to produce one of the first systematic estimates of how common this complication truly is.
The numbers varied modestly by stroke type: 38 percent of intracerebral hemorrhage patients reported post-stroke headaches, compared to 48 percent among those with subarachnoid hemorrhage, yielding an overall pooled rate of 46 percent. The analysis also identified who is most at risk — women consistently showed higher rates across seven studies, and patients with a prior headache history were 4.83 times more likely to develop headaches after their stroke, a striking multiplier that marks past suffering as a strong predictor of future suffering.
Perhaps most sobering was what the researchers did not find: meaningful variation by geography or study setting, which confirms the phenomenon is real and widespread. Yet this consistency in prevalence has produced no corresponding consistency in care. There are virtually no clinical trials testing preventive or treatment strategies for post-stroke headaches, and the field lacks even standardized criteria for diagnosing them.
The researchers called for a foundational reset — agreed-upon diagnostic frameworks, clearly defined patient populations, detailed headache reporting, and above all, rigorous clinical trials. Until that work is done, nearly half of hemorrhagic stroke survivors will face this persistent complication with little more than uncertainty to guide their doctors.
Nearly half of all patients who survive a hemorrhagic stroke will experience headaches in the aftermath, according to a comprehensive analysis of decades of clinical research. The finding, presented at the 2026 American Headache Society annual meeting, draws from 22 rigorous studies examining headache frequency among stroke survivors and represents one of the first systematic attempts to quantify how common this complication truly is.
Dr. Bradley Ashley Ong, a neurologist at the Cleveland Clinic in Ohio, led the effort to search through medical literature published from the field's inception through 2024, combing MEDLINE, PubMed, and the CENTRAL database for any clinical trial or observational study that tracked headaches following hemorrhagic stroke. The team cast a wide net—43 studies made it into the systematic review—but narrowed the focus to 22 that provided clear frequency data and primarily studied adult populations. The precision mattered. Hemorrhagic stroke itself comes in different forms, and the researchers wanted to see whether headache rates varied by type.
They did, slightly. Among patients who suffered an intracerebral hemorrhage—bleeding within the brain tissue itself—38 percent reported headaches afterward. For those with subarachnoid hemorrhage, where bleeding occurs in the space surrounding the brain, the rate climbed to 48 percent. Across both groups, the overall pooled figure settled at 46 percent. That means roughly one in every two people who survives this kind of stroke will contend with headaches as part of their recovery, yet the medical community has little in the way of proven treatments to offer them.
The analysis also identified who faces the highest risk. Women were more likely than men to develop post-stroke headaches, a finding that emerged consistently across seven separate studies. More striking still: patients who had suffered from primary headaches before their stroke—migraines, tension headaches, cluster headaches—were nearly five times more likely to experience headaches after the event. The pooled odds ratio was 4.83, a substantial increase that suggests prior headache history is a powerful predictor of what comes next.
What the researchers did not find was much variation based on geography, economic development, or study quality. Whether a study came from a wealthy nation or a developing one, whether it was conducted in a hospital or community setting, the headache rates remained remarkably consistent. That uniformity suggests the phenomenon is real and widespread, not an artifact of how or where the research was done.
Yet consistency in prevalence has not translated into consistency in treatment. The researchers noted a striking absence: there are virtually no clinical trials testing preventive therapies or secondary prevention strategies for post-stroke headaches. The field lacks standardized diagnostic criteria for identifying and classifying these headaches. Study populations are often poorly defined. Headache characteristics—duration, severity, type, response to medication—are rarely reported in detail. In essence, clinicians know that nearly half their hemorrhagic stroke patients will develop headaches, but they have little guidance on how to prevent them or treat them effectively.
The researchers called for a fundamental shift in how future studies approach the problem. Standardized diagnostic criteria would allow researchers to compare findings across studies and build a coherent body of knowledge. Clearly defined populations would make results more applicable to real patients. Detailed reporting of headache characteristics would help clinicians recognize patterns and tailor interventions. Most urgently, the field needs clinical trials—rigorous tests of preventive and treatment approaches that could transform post-stroke headache from an accepted side effect into a manageable complication. Until that work begins, patients and their doctors will continue navigating this common but poorly understood consequence of hemorrhagic stroke with few tools at hand.
Notable Quotes
Future research should use standardized diagnostic criteria, clearly define study populations, and report detailed headache characteristics. There is also a lack of clinical trials on post-stroke headache treatments, highlighting the need for studies on effective preventive therapies.— Dr. Bradley Ashley Ong and colleagues, Cleveland Clinic
The Hearth Conversation Another angle on the story
Why does it matter that we know exactly how many hemorrhagic stroke patients get headaches? Isn't headache just a minor symptom compared to the stroke itself?
Because half is not minor. That's not a rare side effect—that's a coin flip. And because we don't have treatments for it. If you survive a hemorrhagic stroke, you're already dealing with recovery, rehabilitation, fear. A headache on top of that affects your quality of life, your ability to participate in therapy, your mood. But we don't know how to prevent it or treat it well.
The study found that women and people with prior headaches are at higher risk. Does that mean we could predict who will get post-stroke headaches?
In theory, yes. If a woman comes in with a history of migraines and has a hemorrhagic stroke, we know she's at very high risk. But knowing the risk and being able to do something about it are different things. Right now, we can identify who's vulnerable. We just can't intervene.
Why is there such a gap between knowing the problem exists and having treatments for it?
Because nobody has funded the trials. Post-stroke headache isn't as visible as paralysis or speech problems. It doesn't kill you. So research dollars go elsewhere. But that means millions of stroke survivors are left managing headaches with whatever they can find—often nothing that works well.
What would change if researchers actually ran clinical trials on prevention?
Everything. You'd know which medications work, which don't. You'd have protocols. Doctors could say to a patient: 'You're at risk, so we're going to start you on X.' Right now they can't say that. They're flying blind.
Is this a problem that's getting worse, or has it always been this way?
It's always been this way, but we're only now quantifying it clearly. The meta-analysis is the first real systematic look. That's both good and bad—good because now we have numbers, bad because it took this long to ask the question seriously.